Vaxart Inc
NASDAQ:VXRT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vaxart Inc
NASDAQ:VXRT
|
US |
|
Chemipro Kasei Kaisha Ltd
TSE:4960
|
JP |
|
R
|
Ryde Group Ltd
AMEX:RYDE
|
SG |
|
I
|
IDT International Ltd
HKEX:167
|
HK |
|
S
|
Sichuan Furong Technology Co Ltd
SSE:603327
|
CN |
|
Lynch Group Holdings Ltd
ASX:LGL
|
AU |
|
S
|
Suning Universal Co Ltd
SZSE:000718
|
CN |
|
W
|
Western Securities Co Ltd
SZSE:002673
|
CN |
|
Shakti Pumps India Ltd
NSE:SHAKTIPUMP
|
IN |
|
I
|
Inter Globe Finance Ltd
BSE:511391
|
IN |
|
Saudi Ceramic Company SJSC
SAU:2040
|
SA |
|
K
|
Keller Group PLC
OTC:KLRGF
|
UK |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882
|
CN |
|
Japan Securities Finance Co Ltd
TSE:8511
|
JP |
|
Nighthawk Gold Corp
TSX:NHK
|
CA |
|
F&M Co Ltd
TSE:4771
|
JP |
|
Concurrent Technologies PLC
LSE:CNC
|
UK |
|
M-Resources Group Ltd
HKEX:8186
|
HK |
|
I
|
Iyogin Holdings Inc
TSE:5830
|
JP |
|
E
|
Equity Development Investment Tbk PT
IDX:GSMF
|
ID |
|
T
|
Truwin Co Ltd
KOSDAQ:105550
|
KR |
|
Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601
|
CN |
|
B
|
Bluejay Mining PLC
OTC:BLLYF
|
UK |
Vaxart Inc
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.
Major Partnership: Vaxart signed an exclusive worldwide license agreement with Dynavax for its oral COVID-19 vaccine candidate, potentially worth up to $700 million in license, milestone, and royalty payments.
Upfront Funding: Dynavax will pay $25 million upfront plus a $5 million equity investment, strengthening Vaxart’s cash position and extending its cash runway into Q2 2027.
COVID-19 Program Progress: Vaxart remains on track to deliver multiple data readouts from its Phase IIb COVID-19 trial in 2026, with topline data expected in Q1 and Q4.
Norovirus Program Delay: The next clinical trial for the norovirus vaccine candidate is now expected to begin in 2026, contingent on securing additional funding or a partnership.
Strong Financial Quarter: Q3 revenue surged to $72.4 million, primarily from a BARDA contract, compared to $4.9 million in Q3 2024.
